Biotransformation of a new hypoglycemic agent, N-(p-toluenesulfonyl)-5-methyl-2-pyrazoline-1-carbonamide (SPC-703) in humans and rats.
Over 60% of a dose of N-(p-toluenesulfonyl)-5-methyl-2-pyrazoline-1-carbonamide (SPC-703) given to humans or rats was excreted with urine, one third of the dose was eliminated in unchanged form. From the urine of both species two metabolites of SPC-703, M1 and M2, were isolated and their chemical structures was established. Metabolite M1 is a carboxy- and metabolite M2 a hydroxy derivative of SPC-703.